Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

A decade of advances in treatment for advanced non-small cell lung cancer.

Gettinger S, Lynch T.

Clin Chest Med. 2011 Dec;32(4):839-51. doi: 10.1016/j.ccm.2011.08.017. Review.

PMID:
22054890
2.

New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.

Crawford J.

J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S78-86. Review.

PMID:
19795580
3.

Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.

Custodio A, Méndez M, Provencio M.

Cancer Treat Rev. 2012 Feb;38(1):36-53. doi: 10.1016/j.ctrv.2011.04.001. Epub 2011 May 17. Review.

PMID:
21592673
4.

Targeted therapies for non-small cell lung cancer.

Dempke WC, Suto T, Reck M.

Lung Cancer. 2010 Mar;67(3):257-74. doi: 10.1016/j.lungcan.2009.10.012. Epub 2009 Nov 14. Review.

PMID:
19914732
5.

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.

Kotsakis A, Georgoulias V.

Expert Opin Pharmacother. 2010 Oct;11(14):2363-89. doi: 10.1517/14656566.2010.498581. Review.

PMID:
20586711
6.

EGFR inhibitors: what have we learned from the treatment of lung cancer?

Giaccone G, Rodriguez JA.

Nat Clin Pract Oncol. 2005 Nov;2(11):554-61. Review.

PMID:
16270096
7.

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Vilmar A, Sørensen JB.

Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19. Review.

PMID:
18804893
8.

Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.

Rothschild SI, Gautschi O, Lara PN Jr, Mack PC, Gandara DR.

Curr Opin Oncol. 2011 Mar;23(2):150-7. doi: 10.1097/CCO.0b013e328341ee38. Review.

PMID:
21119513
9.

Predictive molecular markers: has the time come for routine use in lung cancer?

Davies AM, Mack PC, Lara PN Jr, Lau DH, Danenberg K, Gumerlock PH, Gandara DR.

J Natl Compr Canc Netw. 2004 Mar;2(2):125-31. Review.

PMID:
19777702
10.

Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives.

Vilmar AC, Sorensen JB.

Eur Respir Rev. 2011 Mar;20(119):45-52. doi: 10.1183/09059180.00007310. Review.

11.

The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.

Sève P, Reiman T, Dumontet C.

Lung Cancer. 2010 Feb;67(2):136-43. doi: 10.1016/j.lungcan.2009.09.007. Epub 2009 Oct 13. Review.

PMID:
19828208
12.

New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2.

Rodriguez E, Lilenbaum RC.

Clin Lung Cancer. 2008 Nov;9(6):326-30. doi: 10.3816/CLC.2008.n.047. Review.

PMID:
19073514
13.

Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.

Patel JD, Pasche B, Argiris A.

Crit Rev Oncol Hematol. 2004 Jun;50(3):175-86. Review.

PMID:
15182824
14.

Personalized targeted therapy in advanced non-small cell lung cancer.

Ma PC.

Cleve Clin J Med. 2012 May;79 Electronic Suppl 1:eS56-60. doi: 10.3949/ccjm.79.s2.12. Review.

PMID:
22614968
15.

The emerging role of biomarkers in advanced non-small-cell lung cancer.

Socinski MA.

Clin Lung Cancer. 2010 May;11(3):149-59. doi: 10.3816/CLC.2010.n.019. Review.

PMID:
20439190
16.

Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).

Reungwetwattana T, Weroha SJ, Molina JR.

Clin Lung Cancer. 2012 Jul;13(4):252-66. doi: 10.1016/j.cllc.2011.09.004. Epub 2011 Dec 8. Review.

PMID:
22154278
17.

Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).

Langer CJ, Mok T, Postmus PE.

Cancer Treat Rev. 2013 May;39(3):252-60. doi: 10.1016/j.ctrv.2012.05.003. Epub 2012 Jun 14. Review.

PMID:
22703830
18.

Emerging drugs for squamous cell lung cancer.

Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R.

Expert Opin Emerg Drugs. 2015 Mar;20(1):149-60. doi: 10.1517/14728214.2015.1001365. Epub 2015 Jan 5. Review.

PMID:
25557559
19.

Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).

Kumarakulasinghe NB, van Zanwijk N, Soo RA.

Respirology. 2015 Apr;20(3):370-8. doi: 10.1111/resp.12490. Epub 2015 Feb 17. Review. Erratum in: Respirology. 2016 Apr;21(3):567.

20.

[Molecular characteristics of lung cancer].

Bernaudin JF.

Bull Cancer. 2010 Nov;97(11):1323-35. doi: 10.1684/bdc.2010.1211. Review. French.

Supplemental Content

Support Center